Astellas Pharma Inc. (TYO:4503)
Japan flag Japan · Delayed Price · Currency is JPY
1,576.50
-2.00 (-0.13%)
Aug 1, 2025, 3:30 PM JST

Astellas Pharma Company Description

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally.

The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.

It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants.

Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex’s GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution.

Astellas Pharma Inc. was formerly known as Yamanouchi Pharmaceutical Co. Ltd. and changed its name to Astellas Pharma Inc. in April 2005.

The company was founded in 1923 and is headquartered in Tokyo, Japan.

Astellas Pharma Inc.
CountryJapan
Founded1923
IndustryDrug Manufacturers - General
SectorHealthcare
Employees13,643
CEONaoki Okamura

Contact Details

Address:
2-5-1, Nihonbashi-Honcho
Tokyo, 103-8411
Japan
Phone81 3 3244 3000
Websiteastellas.com

Stock Details

Ticker Symbol4503
ExchangeTokyo Stock Exchange
Stock TypeCommon Stock
Fiscal YearApril - March
Reporting CurrencyJPY
ISIN NumberJP3942400007
SIC Code2834

Key Executives

NamePosition
Naoki OkamuraChief Executive Officer
Atsushi KitamuraChief Financial Officer